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R
ecent news of human 
embryonic stem cell (hESC) 
research in Seoul has made 
headlines around the world. In 2004, 
Korea took the world by surprise 
when W. S. Hwang and his team 
published the isolation of hESCs 
from a cloned blastocyst [1]. One 
year later, the same Korean team 
published the establishment of 11 
hESC lines, made from transplanting 
the nucleus of patients’ skin cells into 
donated human oocytes [2]. But few 
in the Western science community 
are aware that hESC research has its 
root in Asia. Ariff Bongso and his 
associates at Singapore’s National 
University Hospital in 1994 were the 
ﬁ  rst to derive hESCs from a ﬁ  ve-day-old 
discarded human embryo and discover 
that these cells were pluripotent and, 
henceforth, had therapeutic potentials 
as cell transplants [3]. Eight years later, 
they were able to substitute the use of 
mouse feeder layer cells with human 
cell feeders and human serum to grow 
hESCs, reducing the risk of introducing 
mouse and bovine pathogens [4] when 
hESCs are transplanted into patients.
 The stem cell success in Korea 
comes out of a history in and growing 
investment in Asia–Paciﬁ  c science that 
the West is slowly appreciating. It also 
comes at a time when independent 
events in the United States are having 
an impact on clinical research and 
health care. The ongoing debate of the 
Right to Life movement versus allowing 
hESC research to ﬁ  ght life-threatening 
diseases continues to polarize public 
opinion. The recent withdrawals of 
rofecoxib (Vioxx), methylphenidate 
(Ritalin), and a few other high-proﬁ  le 
drugs from the market threatens the 
reputation of the pharmaceutical 
industry. Medicine of the 21st-century 
is at a crossroad, with immense changes 
ahead that could change the face of 
the pharmaceutical and health-care 
industry. With these changes, Asia 
is becoming a player in research 
outsourcing to discover new medicine. 
Amazingly, for a latecomer to modern 
drug development, there are now 140 
drugs in China’s pipeline alone, 60 
(10% of the world’s total) of which are 
biologically derived agents, including 
antibodies and vaccines. And in the 
near future, it is likely that numerous 
clinical trials will be performed in Asia 
as clinical trial costs escalate in the 
West. This rise of science in the Asia–
Paciﬁ  c region is not simply fortuitous. 
As I will discuss, it is the result of 
concentrated efforts to capitalize on 
its strengths and to form strategic 
partnerships.
Traditional Chinese Medicine and 
Natural Product Drug Discovery
Traditional Chinese medicine (TCM) 
became a national health-care delivery 
focus when China became the People’s 
Republic of China in 1949. Medicinal 
factories were set up to extract TCMs 
from herbs and to manufacture TCM 
pills and medicinal powders for China’s 
masses. It took another two decades, 
during Nixon’s Ping-Pong Diplomacy, 
for the US to discover the wide use 
of acupuncture in China to treat 
chronic pain. But until very recently, 
TCM has remained an enigma for 
the West. In the 1980s Hong Kong 
became interested in TCM as a focus 
for biotechnology. Today Hong 
Kong researchers collaborate with 
their Chinese counterparts to search 
for herbs with medicinal properties 
by investigating ancient Chinese 
medical literature, and then ﬁ  nding 
the described herbs in the collection 
of herbal libraries in China (Table 
1). For instance, in the search for 
compounds to treat pain, a Chinese 
biotechnology company (International 
Wex Technologies) has successfully 
applied the TCM principle of using one 
poison to counter another—they have 
used sublethal doses of tetrodotoxins 
for the treatment of pain associated 
with heroin withdrawal [5] and for the 
management of pain in patients with 
cancer [6]. 
Most of the active ingredients in 
TCM are uncharacterized, and its 
alleged efﬁ  cacy depends on multiple 
active ingredients from herbal extracts, 
whereas Western medicine often relies 
on the reductive principle of one active 
ingredient to treat a given disease. 
But Western medicine of late has also 
had success in extending the practice 
of combinatorial drug therapy from 
cancer treatment to the combination 
of various anti-HIV drugs to inhibit the 
rapidly mutating virus in patients with 
HIV, and the combination of antibiotics 
and inhibitors of acid secretion for the 
treatment of gastrointestinal ulcers. It 
would appear that Western medicine 
and TCM are beginning to share some 
common ground in the use of more 
than one medicine to treat a disease. 
In 1993, cell signalling research at 
Singapore’s Institute of Molecular 
and Cell Biology (IMCB), where 
I served as the founding director, 
attracted GlaxoWellcome to set 
up a High-Throughput Drug 
Discovery Center in the IMCB to 
screen for lead compounds from 
natural products. This collaboration 
eventually spun off a drug discovery 
company, MerLion Pharmaceutical, 
a Singapore-based company that 
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has the world’s most comprehensive 
and diverse collection of natural 
products (600,000). MerLion is 
collaborating with several companies 
such as Abbott Laboratories, Merck, 
Athelas, NovImmune, Schering–
Plough, KuDOS Pharmaceuticals, 
Fujisawa Pharmaceuticals, and Dow 
AgroSciences to search for lead 
compounds in its impressive collection 
of natural products. High-throughput 
screening, selection of highly speciﬁ  c 
cell-signalling intervention points, and 
computational indexing of libraries 
cover the value chain of modern drug 
discovery, and have been established 
for several years in Singapore. This 
is now bringing in companies from 
around the world to the Asia Paciﬁ  c 
to discover new leads from natural 
products.
Genomics, Gene Therapy, 
and hESCs 
As leadership in Singapore, Hong 
Kong, Taipei, and Seoul were 
considering avenues of biotechnology 
investment in the 1980s, the US 
and Europe had already decided to 
sequence the human genome. Apart 
from Japan, the Asia–Paciﬁ  c region 
was generally unprepared for the 
coming of the age of genomics. By the 
1990s, different pieces of the human 
genome were assigned to different 
countries for sequencing, with the US 
having the lion’s share. Nevertheless, 
Singapore’s IMCB resolved to make a 
meaningful contribution to genomics 
by sequencing the genome of the 
Japanese puffer ﬁ  sh Fugu rubripes. With 
such a small genome (365 megabases) 
and relatively little repetitive DNA, 
the puffer ﬁ  sh offered a potential 
tool to annotate and thereby study 
the human genome. Indeed the 
puffer ﬁ  sh genome sequence enabled 
the Singapore-led team to discover 
approximately 1,000 human putative 
genes that had not been described 
in the public annotation prediction 
databases [7]. 
In the same year, another genome 
feat was being accomplished in China, 
where two US-trained scientists, 
Gane Wong and Jun Yu, persuaded 
the Chinese Academy of Sciences 
to support the genomic sequencing 
of the most important agricultural 
plant in the history of Asia, rice. 
Wong and Yu established the Beijing 
Genomics Center and gathered 500 
young researchers to sequence the 
rice genome. To beat the competition, 
it was not uncommon for young 
researchers to work around the clock, 
camping in the laboratory. And in 
2002, the Beijing Genomics Center 
surprised the world by announcing that 
it had sequenced the rice genome [8]. 
With essentially no track record in the 
ﬁ  eld, IMCB and the Beijing Genomics 
Center made signiﬁ  cant breakthroughs, 
despite being late off the starting block 
in the genomics race. 
Grit and imagination drove Asian 
science to compete with the best 
genomic science in the world. The 
same can be said of both human stem 
cell and gene therapy research in Asia, 
except that the impact is even bigger. 
The ﬁ  rst licensing of a made-in-China 
gene therapy product surprised the 
world. SiBiono Gene Technologies, a 
gene therapy company in Shenzhen, 
announced the world’s ﬁ  rst gene 
therapy medicine, developed using the 
recombinant adenovirus-p53 tumour 
suppressor gene for the treatment 
of head and neck squamous-cell 
carcinoma. In clinical trials, 64% 
of patients with late-stage head and 
neck cancer experienced complete 
regression of their tumours. SiBiono’s 
success was attributed to developing 
the right system for delivery of its 
adenoviral vector. It addressed safety 
by careful dosing and follow-up of the 
patients for up to ﬁ  ve years. 
China’s large patient population base 
means it is easier to recruit patients 
and, hence, generate clinical data 
quickly. Clinical trials of gene therapy 
have not been delayed in China as 
they were in the West because of a 
few fatalities in the US and Europe 
during the initial clinical studies of 
gene therapy. So far, no deaths have 
been reported from gene therapy trials 
in China. The approval of the ﬁ  rst 
gene therapy product has propelled 
China to the forefront of gene therapy 
medicine. There are now ten gene 
therapy products in development in 
China, compared to 43 in the US and 
ten in Europe. Patients with head and 
neck cancer from the US and Europe 
are opting to go to China for gene 
therapy treatment. No doubt the rest of 
the world will closely monitor China’s 
experience with gene therapy when the 
interests of patients worldwide are at 
stake.
Can’t Do, Me Too, or Can Do 
Economies
Some 20 years ago, few scientists in the 
West would have believed that good 
science could come out of Asia within 
their lifetime, since none of the Asian 
countries except Japan had invested 
much into basic biological sciences. 
Only in the early 1980s did the tiger 
economies of Singapore, Hong Kong, 
South Korea, and the Republic of 
China ponder the merit of graduating 
from a “me too” manufacturing 
economy to a “can do”, knowledge-
based society. Could it be done, and, 
if so, how long would it take for these 
countries to build their respective 
critical mass of scientists? 
At that time, Deputy Prime Minister 
of Singapore, Dr. Goh Keng Swee, the 
architect of the Singapore economic 
miracle, asked whether Singapore 
could build an equivalent of the 
Weizmann Institute, a state-funded 
center for scientiﬁ  c excellence. To 
address this question, the Singapore 
IMCB was set up in 1987, and it began 
recruiting young scientists from 
Europe, the US, and Canada. Within 
ten years, the IMCB established an 
infrastructure for intensive research 
in modern biology (http://www.
imcb.a-star.edu.sg). It recruited 300 
scientists working on cell signalling 
mechanisms during differentiation, 
proliferation, development, cell 
movement, and host–virus interactions. 
In as little as one decade, good science 
was fostered from essentially nothing. 
Within another decade, the IMCB 
experiment was expanded to a dozen 
more research institutes focusing 
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Table 1. Treatments Derived from TCMs
Treatment Illness
Arsenic trioxide Acute promyelocytic leukemia [9]
Artimisinin Drug-resistant malaria [10]
Red rice yeast extract High serum cholesterol and C-reactive protein [11]
Yeast extract HIV (R. Ting, personal communication)
Tetrodotoxin Heroin withdrawal [5]; severe, refractory cancer pain [6]
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on translation medicine, genomics, 
neuroscience, nanotechnology, 
bioinformatics, imaging, drug 
discovery, infectious diseases, and 
human disease model systems, all 
housed in the newly built science city 
Biopolis, as well as in universities and 
hospitals. The number of scientists 
working in Singapore has more than 
doubled to 3,000 in the past ten years, 
reﬂ  ecting an apparent emigrational 
trend of scientists from the West to the 
Asia–Paciﬁ  c region. 
If the present is a glimpse of the 
future, there are several signs of things 
to come: Alex Matter, the discoverer 
of the well-known anticancer drug 
imatinib (Gleevec) has established the 
Novartis Institute for Tropical Disease 
Research in Biopolis; David Lane, 
the discoverer of p53 as a tumour 
suppressor, has been recruited to 
succeed myself as Director of IMCB; 
Sydney Brenner has great enthusiasm 
to get the Institute of Translation 
Research going in Singapore; and 
others like George Radda (United 
Kingdom), Axel Ullrich (Germany), 
and K. C. Nicolaou (US) are setting 
up laboratories in Singapore, while 
continuing to maintain their main 
laboratory in the US and Europe. 
Successful senior Asian scientists in the 
US such as neuroscientist M. M. Poo at 
the University of California at Berkeley, 
X. D. Wong at the University of 
Texas Southwestern, Yale University’s 
geneticist T. Xu, Singapore IMCB’s P. 
Li, C. W. Wong of Scripps Research 
Institute, and M. Lai of the University 
of Southern California have all 
recently set up corresponding research 
institutes in China or Taiwan (Taipei).
Movement is also occurring within 
Asia. In 2001, the recruitment of 
a leading cancer researcher at the 
University of Kyoto, Y. Ito, with his 
entire team to Singapore’s IMCB 
created a debate in the Japanese news 
media. Shortly after Ito’s move to 
Singapore, Japan’s Minister of Science 
made a serious effort to accelerate 
reform of modern biology in Japan, 
an exercise its former Minister of 
Education started 20 years ago. 
Although Japan annually invests as 
much as the US on a per capita basis 
in biomedical research, by several 
measures, it is a distant third in the 
world of modern biology. The decision 
was made to build a graduate university 
for modern biology in Okinawa. The 
president of this graduate university 
shall be an eminent scientist from 
outside of Japan; the faculty and the 
students will consist of a cosmopolitan 
mix of non-Japanese and Japanese 
researchers, and the language of 
instruction will be English. The 
purpose is to reform modern biology 
in Japan by enticing promising 
scientists into Japan through Okinawa. 
Will this be a successful experiment 
for Japan even though some consider 
Okinawa too far away from the centers 
of excellence on the main island of 
Japan? 
Good science will ﬂ  ourish wherever 
the conditions are most friendly, as it 
did in the US in the last century. Many 
factors, such as good funding, cost 
per discovery, the ready availability of 
a large pool of young talent, cultural 
acceptability of non-natives to Asian 
societies, and good living conditions 
must be in place. As knowledge-based 
societies become a reality, industry 
worldwide will outsource discovery to 
wherever the job can be done well and 
at the lowest cost. In the 20th century, 
the US was the Mecca of science, 
attracting the giants of science from the 
rest of the world. Economic conditions 
are different today; there is abundant 
wealth and young talent in Asia. For 
Asia to become a Mecca of science 
in the 21st century, countries in the 
region need to take a long-term view 
and be as eager to promote scientiﬁ  c 
collaboration with each other as they 
are to collaborate with the US.
Without a doubt, the science star is 
shining over Asia, but Asian science 
has a glaring deﬁ  ciency in being highly 
“Balkanized”. In Europe, support of 
research crosses national boundaries 
and is facilitated by the European 
Molecular Biology Organization. Today 
research funding crosses few national 
borders in Asia. Notwithstanding 
this, eight years ago a small group 
of visionary scientists led by Ken-
ichi Arai, the former Director of 
the Institute of Medical Sciences at 
the University of Tokyo, formed the 
equivalent of the European Molecular 
Biology Organization in Asia called the 
Asia–Paciﬁ  c International Molecular 
Biology Network. To date the 
Asia–Paciﬁ  c International Molecular 
Biology Network has 300 scientists in 
its network, representing key scientists 
from 16 countries in Asia. In spite of a 
lack of cross-border funding, the Asia–
Paciﬁ  c International Molecular Biology 
Network has managed to conduct 
workshops and symposia annually 
through innovative fundraising 
schemes. Good science is on the move 
in Asia, and when Asia’s talents are 
mobilized, it will move the world as 
never seen before.  
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